AMAL Therapeutics raises 33.2 million dollars
15.11.2018
Share this article
The Geneva-based startup just announced the completion of its Series B financing round, raising in total CHF 33.2 million.
Read Venturelab‘s interview of AMAL Therapeutics‘ CEO and Founder, Madiha Derouazi